Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms

  • STATUS
    Recruiting
  • End date
    Dec 12, 2026
  • participants needed
    80
  • sponsor
    Imago BioSciences,Inc.
Updated on 12 July 2022

Summary

This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in patients with an MPN who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102 and IMG-7289-CTP-201 (referred to hereafter as 'feeder studies').

Details
Condition Thrombocythemia, Essential, Primary Myelofibrosis
Treatment Bomedemstat
Clinical Study IdentifierNCT05223920
SponsorImago BioSciences,Inc.
Last Modified on12 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Completed at least one Treatment Period (TP) in a prior bomedemstat MPN protocol (such as, but not limited to, IMG-7289-CTP-102 or IMG-7289-CTP-201)
In the estimation of the Investigator, the risk-benefit favors continued dosing with bomedemstat

Exclusion Criteria

Ongoing participation in another investigational study (except observational studies)
A history of non-compliance in a prior bomedemstat study (excluding dose suspensions that were medically warranted)
Current use of a prohibited medication (e.g., romiplostim)
Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's safety, ability to give informed consent, or comply with the trial protocol
Females who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study
Women of childbearing potential (WOCBP) and fertile men unwilling to agree to use an approved method of contraception from time of enrollment until 14 days after last bomedemstat dose
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note